March 14, 2024: Relation Therapeutics, the UK’s leading biotechnology firm pioneering the fusion of computational and experimental methodologies in drug discovery, has revealed a new round of seed financing, securing $35 million. This brings the company's total seed funding to $60 million.

The recent funding round was led by the California based venture capitalist, DCVC with NVentures, the venture arm of NVIDIA, as co-leader. Magnetic Ventures, Khosla Ventures, and Abcam founder Jonathan Milner, who were initial seed investors, participated, alongside new investors ARK Invest and Deerfield Management Company.

David Roblin, CEO of Relation Therapeutics, said in the company's press release,  "This new capital allows us to accelerate our discovery of novel biology, targets and medicines: we are immensely excited about our progress and the impact we can make for patients."

Led by seasoned drug developers, computational scientists, and entrepreneurs, the company utilises advanced technologies to collect, analyse, and interpret human data on gene, cell, and tissue behaviour in an unmatched manner. Leveraging this, the company identifies new targets and proceeds with drug development. The raised funds will facilitate the advancement of Relation's osteoporosis pipeline to clinical stages and the initiation of discovery efforts in critical therapeutic areas with unmet needs.

Relation Therapeutics is initially focusing on developing therapies for osteoporosis. Additionally, the company has established proprietary data resources, such as Osteomics, which is a clinical observational study aimed at creating the largest functional single-cell bone atlas derived from human patient tissue. Utilising a Lab-in-the-Loop approach, Relation integrates single-cell multi-omics directly from patient tissue, along with functional assays and machine learning, to comprehend biological processes in human health and disease. Leveraging its technology and data insights, Relation is swiftly progressing its programs, particularly in addressing bone-related diseases.

The goal is to grasp the intricacies of human biology like never before, uncovering treatments for some of the most severe diseases known to mankind. This significant financial backing not only validates the company's strategic vision but also positions Relation Therapeutics favourably for future milestones and opportunities to make a meaningful impact in addressing unmet medical needs and improving patient outcomes.